Next Generation News and Research

RSS

American Medical Alert second-quarter net income increases 30% to $791,418

American Medical Alert Corp.a provider of healthcare communication services and advanced telehealth monitoring technologies, today announced operating results for the quarter and six months ended June 30, 2010.

12 Aug 2010

Sage Science introduces Pippin Prep DNA size selection system in US markets

Sage Science, Inc. announced today the release of the Pippin Prep DNA size selection system to the United States market. This device automates the collection of DNA fragments for next generation sequencing library preparations, and replaces manual gel purification techniques that typically require hours of effort.

12 Aug 2010

Dicerna announces closing of $25 million Series B round of financing

Dicerna Pharmaceuticals, Inc., a second generation RNA interference company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA molecules, today announced that it has closed a $25 million Series B round of financing. New investor Domain Associates led the round, with all existing investors participating - Oxford Bioscience Partners, Skyline Ventures and Abingworth.

11 Aug 2010

New optical imaging technique holds potential to improve angioplasty

A new optical imaging technique described in the journal Review of Scientific Instruments, which is published by the American Institute of Physics, holds the potential to greatly improve angioplasty, a surgery commonly performed to treat patients with a partially or completely blocked coronary artery that restricts blood flow to the heart.

11 Aug 2010

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has received preliminary results from a Phase II clinical trial of GDC-0449 from Roche and Genentech, Curis' collaborator and a member of the Roche Group.

9 Aug 2010

Taiyo Pacific Partners becomes third largest shareholder in CMIC

Taiyo Pacific Partners announced today that it has accumulated a position in excess of 5% in CMIC Co., Ltd. (2309) to become its third largest shareholder. Taiyo Pacific Partners is known for its cooperative investment style working with senior management to enhance shareholder value.

7 Aug 2010

BIO-key International awards contract for fingerprint biometric identity solution

BIO-key International, Inc., a leader in finger-based biometric identification solutions announced the award of another contract for a fingerprint biometric identity solution built on the fusion of BIO-key and MorphoTrak algorithms. The first contract for this fused solution, awarded to MorphoTrak (a Morpho company) by Lockheed Martin in September 2009, provides fingerprint identification technology for the FBI's Next Generation Identification (NGI) system. This new contract will provide large scale advanced finger matching technology to an overseas customer.

6 Aug 2010

Scientists find new way to make beating heart cells from body's own cells

Scientists at the Gladstone Institute of Cardiovascular Disease have found a new way to make beating heart cells from the body's own cells that could help regenerate damaged hearts. Over 5 million Americans suffer from heart failure because the heart has virtually no ability to repair itself after a heart attack.

6 Aug 2010

WaferGen launches SmartChip System for discovery, validation of biomarkers

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, today announced it has launched the breakthrough WaferGen SmartChip Real-Time PCR System, the next-generation Real-Time PCR system for discovery and validation of biomarkers, or gene expression patterns, on a single platform. The SmartChip System is designed to provide accurate, highly sensitive and high-throughput gene expression profiling capabilities to researchers, clinicians and pharmaceutical companies.

6 Aug 2010

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Life Technologies Corporation and the University of California at San Diego Moores Cancer Center today announced a partnership to use SOLiD 4 genomic analysis technology in a research program to study chronic lymphocytic leukemia, a cancer of the white blood cells. The CLL research is made possible by funding from the National Institutes of Health and will enable scientists to survey the whole transcriptomes of 96 CLL tumor samples for potential biomarkers.

5 Aug 2010

Micromet second-quarter 2010 total revenues increase to $6.5 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

Columbia second-quarter net revenues from progesterone products increase 48% to $8.4 million

Columbia Laboratories, Inc. today announced financial results for the three- and six-month periods ended June 30, 2010.

5 Aug 2010

ECRI Institute and Silverchair relaunch AHRQ's updated NGC, NQMC Web sites

ECRI Institute, an independent nonprofit that researches the best approaches to improving patient care, and its technology subcontractor, Silverchair, today announce the relaunch of two key healthcare Web sites they have developed for the U.S. Agency for Healthcare Research and Quality (AHRQ). The National Guideline Clearinghouse™ (NGC™), www.guideline.gov, and the National Quality Measures Clearinghouse™ (NQMC™), www.qualitymeasures.ahrq.gov, now feature updated design elements, enhanced search functionality, and easier access to all content.

5 Aug 2010

Optimer second-quarter net loss decreases to $10.4 million

Optimer Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010. Optimer reported a net loss for the second quarter of 2010 of $10.4 million, or $0.27 per share, which was in line with the Company's expectations. This compares to a net loss for the second quarter of 2009 of $12.4 million, or $0.37 per share. The decrease in net loss was primarily due to lower research and development expenses offset by an increase in general and administrative expenses.

5 Aug 2010

Sigma-Aldrich, NHLBI and BU collaborate in atherosclerotic cardiovascular disease research

Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.

5 Aug 2010

Amplimmune collaborates with GSK to develop PD-1 targeting therapies

Amplimmune, Inc. today announced that it has entered into a broad strategic alliance with GlaxoSmithKline (GSK) to further develop PD-1 targeting therapies that may be effective in the treatment of cancer and other diseases. GSK will obtain exclusive worldwide rights to AMP-224 as well as other potential next generation fusion proteins that target PD-1.

5 Aug 2010

Discovery Laboratories reports net loss of $6.3 million for second-quarter 2010

Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant and related aerosolization technologies as first in class therapies for severe respiratory diseases, today provides an update on key pipeline and business initiatives and reports financial results for the second quarter ended June 30, 2010.

4 Aug 2010

BioClinica second-quarter service revenues increase to $15.7 million

BioClinica, Inc., a global provider of clinical trial management services, today announced its financial results for the second quarter and six months ended June 30, 2010.

From Clario 4 Aug 2010

Carfilzomib could become new option for patients with relapsed myeloma, IMF says

The International Myeloma Foundation, the oldest and largest foundation dedicated to improving the life and care of myeloma patients, today said promising data suggest a new drug called carfilzomib could become an important new option for patients whose myeloma stops responding to other therapies.

4 Aug 2010

Glycotope receives German, Italian regulatory approval for CetuGEX Phase I study for solid cancers

Glycotope GmbH, a leading glycobiology company, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope´s next generation antibody CetuGEX™ (GT-MAB 5.2-GEX) for the treatment of various solid cancers.

4 Aug 2010

Next Generation News and Research

American Medical Alert second-quarter net income increases 30% to $791,418

Sage Science introduces Pippin Prep DNA size selection system in US markets

Dicerna announces closing of $25 million Series B round of financing

New optical imaging technique holds potential to improve angioplasty

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Taiyo Pacific Partners becomes third largest shareholder in CMIC

BIO-key International awards contract for fingerprint biometric identity solution

Scientists find new way to make beating heart cells from body's own cells

WaferGen launches SmartChip System for discovery, validation of biomarkers

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Micromet second-quarter 2010 total revenues increase to $6.5 million

Columbia second-quarter net revenues from progesterone products increase 48% to $8.4 million

ECRI Institute and Silverchair relaunch AHRQ's updated NGC, NQMC Web sites

Optimer second-quarter net loss decreases to $10.4 million

Sigma-Aldrich, NHLBI and BU collaborate in atherosclerotic cardiovascular disease research

Amplimmune collaborates with GSK to develop PD-1 targeting therapies

Discovery Laboratories reports net loss of $6.3 million for second-quarter 2010

BioClinica second-quarter service revenues increase to $15.7 million

Carfilzomib could become new option for patients with relapsed myeloma, IMF says

Glycotope receives German, Italian regulatory approval for CetuGEX Phase I study for solid cancers

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News